Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture (Q33902419)

29 July 2017

1 reference

title

Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture (English)

1 reference

29 July 2017

1 reference

1 reference

Jans Fromow-Guerra

13

0 references

Mauricio Maia

object named as

Mauricio Maia

5

0 references

Lihteh Wu

4

object named as

Lihteh Wu

1 reference

29 July 2017

J Fernando Arevalo

1

1 reference

29 July 2017

Juan G Sanchez

2

1 reference

29 July 2017

Andres F Lasave

3

1 reference

29 July 2017

Sergio Bonafonte

6

1 reference

29 July 2017

Miguel Brito

7

1 reference

29 July 2017

Arturo A Alezzandrini

8

1 reference

29 July 2017

Natalia Restrepo

9

1 reference

29 July 2017

Maria H Berrocal

10

1 reference

29 July 2017

Mario Saravia

11

1 reference

29 July 2017

Michel Eid Farah

12

1 reference

29 July 2017

Virgilio Morales-Canton

14

1 reference

29 July 2017

language of work or name

1 reference

30 March 2011

1 reference

29 July 2017

Journal of Ophthalmology

1 reference

29 July 2017

2011

1 reference

29 July 2017

584238

1 reference

Creative Commons Attribution 3.0 Unported

29 July 2017

start time

1 January 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090772

Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090772

Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090772

Vascular endothelial growth factor: basic science and clinical progress

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090772

Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090772

VEGF and the quest for tumour angiogenesis factors

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090772

Inflammatory response after scatter laser photocoagulation in nonphotocoagulated retina.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090772

Quantitative analysis of diabetic macular edema after scatter laser photocoagulation with the scanning retinal thickness analyzer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090772

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090772

Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090772

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090772

Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090772

Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090772

Diabetic maculopathy. A critical review highlighting diffuse macular edema

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090772

Macular edema. A complication of diabetic retinopathy

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090772

Single versus Multiple Treatment Sessions of Argon Laser Panretinal Photocoagulation for Proliferative Diabetic Retinopathy

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090772

Visual loss following panretinal photocoagulation for proliferative diabetic retinopathy

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090772

Vascular endothelial growth factor is a secreted angiogenic mitogen

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090772

Global and societal implications of the diabetes epidemic

28 July 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F584238

Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy

21 January 2018

2 references

https://api.crossref.org/works/10.1155%2F2011%2F584238

21 January 2018

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3090772

Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate

29 October 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F584238

A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F584238

Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F584238

Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F584238

Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F584238

Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F584238

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F584238

Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F584238

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F584238

Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F584238

Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F584238

Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F584238

Testing intravitreal toxicity of bevacizumab (Avastin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F584238

Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F584238

Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F584238

Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F584238

Supplemental oxygen improves diabetic macular edema: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F584238

Extensive argon laser photocoagulation in the treatment of proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F584238

Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F584238

Vascular-specific growth factors and blood vessel formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F584238

Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F584238

Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment

21 January 2018

1 reference

12 December 2020

Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases

1 reference

12 December 2020

Quantifying alterations of macular thickness before and after panretinal photocoagulation in patients with severe diabetic retinopathy and good vision

1 reference

12 December 2020

Rapid resolution of severe disc new vessels in proliferative diabetic retinopathy following a single intravitreal injection of bevacizumab (Avastin)

1 reference

12 December 2020

Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group

1 reference

12 December 2020

The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema

1 reference

12 December 2020

Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group

1 reference

12 December 2020

Randomized comparison of krypton versus argon scatter photocoagulation for diabetic disc neovascularization. The Krypton Argon Regression Neovascularization Study report number 1

1 reference

12 December 2020

Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): results of the Pan-American Collaborative Retina Study Group (PACORES)

1 reference

12 December 2020

Factors associated with visual outcome after photocoagulation for diabetic retinopathy. Diabetic Retinopathy Study Report #13

1 reference

12 December 2020

Vanishing disc neovascularization following intravitreal bevacizumab (avastin) injection

1 reference

12 December 2020

A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema

1 reference

12 December 2020

Macular edema in Diabetic Retinopathy Study patients. Diabetic Retinopathy Study Report Number 12

1 reference

12 December 2020

Identifiers

DOI

10.1155/2011/584238

1 reference

29 July 2017

1 reference

29 July 2017

1 reference